Three previous rallies to the 200-day average failed, but this one may be different.
AGN will not be in an uptrend until it can move above $250.
Each bounce in the stock has been followed by a move to lower lows.

Biogen: Quality at a Discount Real Money Pro($)

Biotechs now offer some great valuations, and BIIB is prime example.
Valeant could 'completely implode' if sales are misplayed, says the activist investor.
Traders and investors should either stand aside or start probing the short side.
But buying anything associated with VRX will make you feel dirty.
A close below $135 would be a near-term caution flag.
A breakdown below $33 would mean sellers have gained the upper hand.
As Brexit turmoil calms down, let's get back to small cap stocks.


News Breaks

Powered by


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.